| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03308786 Details | 2022-09-28 Interventional | 2 | 9 | Aldesleukin Interleukin-2 HIV Infections HIV Infection | There were 3 instances of adverse events which were discussed with external safety monitoring
committee and it was recommended that the study be terminated. On the basis of recommendation of the SMC, the study was terminated. Because of this, the primary objective could not be achieved and most of the secondary objectives could not be achieved. | |||
| NCT01407562 Details | 2022-09-28 Interventional | 1 | 34 | Carboplatin Paclitaxel Neoplasms Breast Cancer -… Unspecified Adu… | - - | |||
| NCT04282174 Details | 2022-09-27 Interventional | 2 | 0 | Busulfan Cyclophosphamid… Fludarabine Melphalan Thiotepa Hematologic Dis… Hematologic Neo… Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Neoplasms Precursor Cell … Acute Lymphobla… Acute Myeloid L… Chronic Lymphoc… Chronic Myeloge… Hematologic Mal… | Study was split into two new studies before the first participant was enrolled. - | |||
| NCT02388178 Details | 2022-09-27 Interventional | 2 | 0 | Fluorides Dental Caries | The study was stopped due to business reasons. - | |||
| NCT02562443 2015-001476-22 Details | 2022-09-26 Interventional | 3 | [1 Refs] | 372 | ON 01910 Anemia, Refract… Anemia, Refract… Myelodysplastic… Preleukemia Syndrome MDS Myelodysplastic… RAEB Refractory Anem… | Top line analysis indicated that the study had failed to achieve its primary endpoint. - | ||
| NCT02943733 Details | 2022-09-23 Interventional | 1 | 18 | Temozolomide Neoplasms Neuroendocrine … Cancer Tumors | closed per sponsor request, for slow enrollment - | |||
| NCT02818894 Details | 2022-09-23 Interventional | 4 | 135 | Bupivacaine Lidocaine Total Hip Arthr… | This study was terminated due to pressing matters related to the COVID-19 pandemic - staff
shortages and changes of personnel, data gaps due to the pandemic, participants not being able
to continue follow-up visits, and ongoing enrollment issues. The study was terminated due to extended suspension of the study related to personnel issues and pandemic-related issues. Missing data due to lost study records limited the number of available data points. | |||
| NCT05268497 Details | 2022-09-22 Interventional | 1 | 0 | Antidepressive … Esketamine Depression Depressive Diso… Depressive Diso… | due to budget decision and wanting to pursue other research priorities - | |||
| NCT04407390 Details | 2022-09-22 Interventional | 2 | 0 | Niacin Niacinamide Nicotinic Acids COVID-19 COVID | No volunteers where recruited to this study. Other studies were prioritised over this at the
time of enrollment. - | |||
| NCT04080076 Details | 2022-09-22 Interventional | 4 | 0 | Tacrolimus Kidney Diseases Renal Disease | Study was updated and issued a new NCT number. - | |||
| NCT03712787 2018-000268-26 Details | 2022-09-22 Interventional | 2 | 364 | Tilavonemab Alzheimer Disea… Alzheimer's Dis… | Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956). Study M15-570 was discontinued because of lack of efficacy in the parent study (Study M15-566) and 2) the tilavonemab development program was discontinued. | |||
| NCT04906382 Details | 2022-09-21 Interventional | 1 | 2 | Albumin-Bound P… Carboplatin Paclitaxel Tislelizumab Adenocarcinoma,… Carcinosarcoma Colorectal Neop… Endometrial Neo… Mixed Tumor, Mu… Recurrence Lynch Syndrome Metastatic Endo… Mismatch Repair… Recurrent Endom… Recurrent Endom… Recurrent Endom… Recurrent Uteri… | Sponsor reorganization - | |||
| NCT04567225 Details | 2022-09-21 Interventional | 4 | 39 | Insulin Glargin… Acidosis Diabetes Mellit… Diabetic Ketoac… Ketosis Type 1 Diabetes Type 2 Diabetes | Stopped after internal review The study was closed due to lack of proper resource availability. Since study could not be completed as planned, no analysis was completed. | |||
| NCT04265534 Details | 2022-09-21 Interventional | 2 | 40 | Carboplatin Dexamethasone Folic Acid Pembrolizumab Pemetrexed Vitamin B 12 Carcinoma, Non-… Lung Neoplasms KEAP1 Gene Muta… NFE2L2 Gene Mut… NRF2 Gene Mutat… Non-Small Cell … Non-Squamous No… Non-squamous No… | Lack of Clinical Benefit - | |||
| NCT03417492 Details | 2022-09-21 Interventional | 1 | 7 | Citric Acid Sildenafil Citr… Sodium Citrate Brain Concussio… Brain Injuries Brain Injuries,… Post-Concussion… Wounds and Inju… Mild Traumatic … Traumatic Brain… | Difficulty enrolling participants due to COVID emergency, and planned start of new study to
address this question in a more rigorous fashion. - | |||
| NCT03273153 2016-004387-18 Details | 2022-09-21 Interventional | 3 | 446 | Atezolizumab Pembrolizumab Melanoma Advanced BRAFV6… | This study was terminated due to benefit/risk analysis. - | |||
| NCT01902290 2012-003351-11 Details | 2022-09-21 Interventional | 2 | 421 | Brodalumab Asthma | Study terminated early due to lack of efficacy observed following interim analysis in Q2 2015.
Study Closed once all sites were closed in eClinical - | |||
| NCT04830982 Details | 2022-09-19 Interventional | 1 | 0 | Diazoxide Myocardial Stun… | Withdrawn in IRB. - | |||
| NCT04189952 Details | 2022-09-19 Interventional | 2 | 2 | Acalabrutinib Carboplatin Etoposide Ifosfamide Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… Lymphoma, Large… Chronic Lymphoc… Diffuse Large B… Marginal Zone L… Small Lymphocyt… | Investigator Decision To protect participant privacy and maintain confidentiality, results will not be reported. | |||
| NCT04959266 Details | 2022-09-16 Interventional | 1 | 5 | Adavosertib Itraconazole Omeprazole Rifampin Advanced Solid … | The study terminated because the clinical development programme for Adavosertib has been
discontinued - |